1. Sep 4, 2017 — Researchers at the University of Washington have developed a smartphone app that could detect the early signs of pancreatic cancer by analyzing users' selfies. 2. Sep 4, 2017 — North Korea conducted its sixth and most powerful nuclear test at the underground Punggye-ri Nuclear Test Facility on Sunday. 3. Sep 4, 2017 — Explosives experts in Frankfurt on Sunday defused a massive bomb — a remnant of the last World War more than 70 years ago. 4. Sep 4, 2017 — Governor Jerry Brown declared a state of emergency in Los Angeles County on Sunday as firefighters continued to battle a 5,900-acre brush fire north of downtown Los Angeles. 5. Sep 4, 2017 — A police officer set to be fired after he was caught on camera saying "we only kill black people" is being allowed to immediately retire instead. ------------------------------------------------------------- Go to https://www.patreon.com/tomonews and become a Patron now TomoNews is now on Patreon and we've got some cool perks for our hardcore fans. TomoNews is your best source for real news. We cover the funniest, craziest and most talked-about stories on the internet. Our tone is irreverent and unapologetic. If you’re laughing, we’re laughing. If you’re outraged, we’re outraged. We tell it like it is. And because we can animate stories, TomoNews brings you news like you’ve never seen before. Visit our official website for all the latest, uncensored videos: http://us.tomonews.com Check out our Android app: http://bit.ly/1rddhCj Check out our iOS app: http://bit.ly/1gO3z1f Get top stories delivered to your inbox everyday: http://bit.ly/tomo-newsletter See a story that should be animated? Tell us about it! Suggest a story here: http://bit.ly/suggest-tomonews Stay connected with us here: Facebook http://www.facebook.com/TomoNewsUS Twitter @tomonewsus http://www.twitter.com/TomoNewsUS Google+ http://plus.google.com/+TomoNewsUS/ Instagram @tomonewsus http://instagram.com/tomonewsus
Просмотров: 4043 TomoNews US
SEATTLE — Researchers at the University of Washington have developed a smartphone app that could detect the early signs of pancreatic cancer by analyzing users' selfies. Bilirubin is a bile pigment produced when the liver breaks down old red blood cells. One of the symptoms of pancreatic cancer is jaundice, caused by an accumulation of bilirubin in the body. "The eyes are a really interesting gateway into the body -- tears can tell you how much glucose you have, sclera can tell you how much bilirubin is in your blood," Shwetak Patel, senior author of the study and a professor in computer science and engineering at the University of Washington said in a statement quoted by Medical Daily. The BiliScreen app is used in conjunction with a 3D printed box that controls light exposure for the eye, or with paper glasses that helps calibrate color. After the user has taken a selfie, the app's computer vision algorithms and machine learning tools can spot even the slightest increase in bilirubin levels in the sclera. The app is designed to help people get early treatment if needed, however it cannot replace a blood test. ------------------------------------------------------------- Go to https://www.patreon.com/tomonews and become a Patron now TomoNews is now on Patreon and we've got some cool perks for our hardcore fans. TomoNews is your best source for real news. We cover the funniest, craziest and most talked-about stories on the internet. Our tone is irreverent and unapologetic. If you’re laughing, we’re laughing. If you’re outraged, we’re outraged. We tell it like it is. And because we can animate stories, TomoNews brings you news like you’ve never seen before. Visit our official website for all the latest, uncensored videos: http://us.tomonews.com Check out our Android app: http://bit.ly/1rddhCj Check out our iOS app: http://bit.ly/1gO3z1f Get top stories delivered to your inbox everyday: http://bit.ly/tomo-newsletter See a story that should be animated? Tell us about it! Suggest a story here: http://bit.ly/suggest-tomonews Stay connected with us here: Facebook http://www.facebook.com/TomoNewsUS Twitter @tomonewsus http://www.twitter.com/TomoNewsUS Google+ http://plus.google.com/+TomoNewsUS/ Instagram @tomonewsus http://instagram.com/tomonewsus
Просмотров: 7158 TomoNews US
This webinar will explore familial patterns of pancreatic cancer, hereditary risk and precursors for pancreatic cancer. This webinar was recorded on March 11, 2015. The presenter is Teresa A. Brentnall, MD – University of Washington
Просмотров: 2990 Pancreatic Cancer Action Network
Dr. Joo Ha Hwang, Associate Professor of Medicine (Gastroenterology) at the University of Washington, discusses gaps in current therapies and the role focused ultrasound could play in treating this disease.
Просмотров: 426 Focused Ultrasound Foundation
A lot has been said about the narcissism of the selfie-taking generation, but it does have an upside. Researchers at the University of Washington have developed an app that can diagnose pancreatic cancer just by taking a selfie. According to DigitalTrends.com, the mobile app can screen for one of the deadliest forms of cancer in a non-invasive way. The app uses a smartphone camera, computer vision algorithms, and machine-learning tools to detect jaundice. In an initial clinical study of 70 people, the app correctly identified cases of concern 89.7% of the time. https://www.digitaltrends.com/cool-tech/pancreatic-cancer-screen-selfie/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Просмотров: 107 Wochit News
Gabriela Chiorean, MD, associate professor of Medicine at the University of Washington, discusses adverse events of the phase I study of combination therapies for patients with pancreatic cancer.
Просмотров: 169 OncLiveTV
A smartphone app developed by researchers at the University of Washington could diagnose the early stages of pancreatic cancer, according to a new study in Pediatrics.
Просмотров: 286 Global1 News Network
Dr. Lee Wilke is a surgical oncologist with UW Health and the University of Wisconsin Carbone Cancer Center in Madison, Wisconsin. She specializes in benign and malignant diseases of the breast; sentinel lymph-node mapping and neoadjuvant therapy for breast cancer.
Просмотров: 7361 UW Health
Visit http://archive.nextanimationstudio.com or contact firstname.lastname@example.org to license this or any News Direct video For story suggestions please contact email@example.com RESTRICTIONS: NONE Researchers at the University of Washington have developed a smartphone app that could detect the early signs of pancreatic cancer by analyzing users' selfies. Bilirubin is a bile pigment produced when the liver breaks down old red blood cells. One of the symptoms of pancreatic cancer is jaundice, caused by an accumulation of bilirubin in the body. "The eyes are a really interesting gateway into the body -- tears can tell you how much glucose you have, sclera can tell you how much bilirubin is in your blood," Shwetak Patel, senior author of the study and a professor in computer science and engineering at the University of Washington said in a statement quoted by Medical Daily. The BiliScreen app is used in conjunction with a 3D printed box that controls light exposure for the eye, or with paper glasses that helps calibrate color. After the user has taken a selfie, the app's computer vision algorithms and machine learning tools can spot even the slightest increase in bilirubin levels in the sclera. The app is designed to help people get early treatment if needed, however it cannot replace a blood test. RUNDOWN SHOWS: 1. Bilirubin found in bile 2. Jaundice and pancreatic cancer 3. App uses with 3D printed box or paper glasses; user takes selfie 4. App shows bilirubin levels in the sclera VOICEOVER (in English): "Bilirubin is a bile pigment produced when the liver breaks down old red blood cells." "One of the symptoms of pancreatic cancer is jaundice, caused by an accumulation of bilirubin in the body." "The BiliScreen app is used in conjunction with a 3D printed box that controls light exposure for the eye, or with paper glasses that helps calibrate color." "After the user has taken a selfie, the app's computer vision algorithms and machine learning tools can spot even the slightest increase in bilirubin levels in the sclera." SOURCES: University of Washington, Medical Daily https://ubicomplab.cs.washington.edu/publications/biliscreen/ http://www.medicaldaily.com/selfie-app-detects-pancreatic-cancer-measuring-bilirubin-levels-eyes-421801 *** For story suggestions please contact firstname.lastname@example.org For technical and editorial support, please contact: Asia: +61 2 93 73 1841 Europe: +44 20 7542 7599 Americas and Latam: +1 800 738 8377 ------------------------------------------------------------------------------------------------ Next Animation Studio’s News Direct service provides daily, high-quality, informative 3D news animations that fill in for missing footage and help viewers understand breaking news stories or in-depth features on science, technology, and health. Sign up for a free trial of News Direct's news animations at http://newsdirect.nextanimationstudio.com/trial/ To subscribe to News Direct or for more info, please visit: http://newsdirect.nextanimationstudio.com
Просмотров: 467 News Direct
Dr. Cheng joined Fox Valley Surgical Associates in 2001, providing Fox Valley residents with convenient access to a highly skilled surgical oncologist. His expertise allows patients to have highly complex and advanced cancer surgery in the Fox Valley, surgery that previously required trips to Madison, Milwaukee or the Mayo Clinic. His philosophy is clear: “I strive to stay on top of the latest techniques and make the right decisions to achieve the best outcome for each patient I see.” As a dedicated expert in his field, Dr. Cheng received the Vogel award for outstanding graduating chief resident in the Department of Surgery at the University at Buffalo. Dr. Cheng completed his clinical fellowship in surgical oncology at Roswell Park Cancer Institute. He has been involved in notable projects, research articles and presentations to further hone his expertise. Dr. Cheng’s work has been published in articles in surgical journals and presented at national and international conferences. His work includes Thymidine Phosphorylase Expression in Colorectal Cancer Specimens (Roswell Park Cancer Institute, 2000-2001), Feasibility of Early Oral Feeding Following Colectomy (The Society of Surgical Oncology Annual Meeting, Washington D.C., 2001) and Sentinel Node Biopsy in Malignant Melanoma (The 17th International AEK Cancer Congress, Rio de Janeiro, Brazil). Education Bachelor of Arts-University of California Berkeley 1985-1989 State University of New York Health Science Center at Brooklyn 1990-1992 Doctor of Medicine -University of Southern California School of Medicine 1992-1994 Medical College of Pennsylvania, Department of Surgery 1994-1995 State University of New York at Buffalo, Department of Surgery 1995-1999 License/Certification Wisconsin State License American Board of Surgery 2001, 2011 Graduate Training Residency- General Surgery- Medical College of Pennsylvania 1994-1995 Residency- General Surgery- State University of New York at Buffalo 1995-1999 Fellowship- Surgical Oncology-Roswell Park Cancer Institute 1999-2001 Post Graduate Training Roswell Park Cancer Institute, Fellow in Surgical Oncology 1999-2001 American College of Surgeons American Society of Clinical Oncology American Society for Gastrointestinal Endoscopy Society of American Gastrointestinal and Endoscopic Surgeons Society of Surgical Oncology Comission on Cancer
Просмотров: 17 Fox Valley Surgical Associates
Presented at: cancer Research & Oncology 2017 - https://www.labroots.com/virtual-event/cancer-research-oncology-2017 Presented by: Brad Nelson, PhD - Distinguished Scientist and Director, Deeley Research Centre, Co-Director, Cancer Immunotherapy Program, BC Cancer Agency Biography: Dr. Nelson is a native of Vancouver BC. He received his B.Sc. from the University of British Columbia in 1987 and Ph.D. from the University of California at Berkeley in 1991. He completed postdoctoral training with Dr. Phil Greenberg and held faculty positions at the Fred Hutchinson Cancer Research Center and University of Washington in Seattle. In 2003, he became the founding Director of the BC Cancer Agency's Deeley Research Centre in Victoria BC. He is a Professor of Medical Genetics at the University of British Columbia and a Professor of Biochemistry/Microbiology at the University of Victoria. Dr. Nelson's lab uses genomic and molecular approaches to study the immune response to cancer, with an emphasis on ovarian cancer. As Co-Director of the BCCA's Immunotherapy Program, he is leading a phase I clinical trials program focused on adoptive T cell therapy for gynecological cancers, leukemia, lymphoma, and other malignancies. Webinar: Immunotherapy: A revolution in cancer treatment Abstract: Immunotherapy: An unprecedented opportunity -Long-lasting/curative treatments -Lower side effects -Wide applicability -Natural mechanism of action -Locally produced T cell therapies -jobs -talent -innovation -intellectual property -cost control Earn PACE/CME Credits: 1. Make sure you’re a registered member of LabRoots - https://www.labroots.com/virtual-event/cancer-research-oncology-2017 2. Watch the webinar on YouTube above or on the LabRoots Website - https://www.labroots.com/virtual-event/cancer-research-oncology-2017 3. Click Here to get your PACE (Expiration date – October 12, 2019 09:00 AM) - http://www.labroots.com/credit/pace-credits/2482/third-party 4. Click here to get your CME credits (Expiration date – Jan. 11 2018 06:00 A.M.) – https://www.surveymonkey.com/r/52H7TV9 LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Просмотров: 506 LabRoots
"Prostatectomy versus Watchful Waiting among elderly patients with clinically localized Prostate Cancer: Exploring heterogeneity in Survival Effects" (with John Gore): Video and Slides. 2nd September, NUI Galway
Просмотров: 213 ECRG NUI Galway
UW Medicine's 2014 Mini-Medical School is a series of lectures and demonstrations designed to teach viewers about medical science, patient care and leading-edge research underway at the University of Washington. Taking healthcare communications and personalized medicine for cancer care to the next level. Part two is presented by Doctor Eric Holland, from the UW School of Medicine and Fred Hutchinson Cancer Research Center. Eric Holland, M.D., Ph.D., professor, UW Department of Medicine, Neurological Surgery 03/04/2014 Health and Medicine http://uwtv.org
Просмотров: 117 UW Video
A research team at University of Washington has developed a smartphone app that allows users to screen for pancreatic cancer by taking a selfie. The app, which is called, BiliScreen, uses smartphone's camera as well as computer vision algorithms and machine learning tools to detect increased levels of bilirubin in a person's sclera, the white part of the eye. One of the earliest symptoms of pancreatic cancer is jaundice, a yellowing of the skin and eyes caused by an increase in bilirubin in the blood. A statement from the team said this week, "The hope is that if people can do this simple test once a month -- in the privacy of their own homes -- some might catch the disease early enough to undergo treatment that could save their lives." https://www.upi.com/Health_News/2017/08/28/App-uses-smartphone-selfies-to-screen-for-pancreatic-cancer/9681503947051/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Просмотров: 502 Wochit News
Presented at Cancer Research & Oncology 2017 Lynn Matrisian, PhD, MBA - Chief Science Officer, Pancreatic Cancer Action Network Lynn M. Matrisian, PhD, MBA, is Chief Science Officer at the Pancreatic Cancer Action Network, based in Manhattan Beach, CA and Washington DC. She focuses on understanding and impacting the scientific and medical activities within the pancreatic cancer field to advance the organizations goal to double survival from pancreatic cancer by the year 2020. She has oversight of the organization's research activities, including the Grants Program, Clinical Trial Finder, Patient Registry, Know Your Tumor and Early Detection Initiative, and sits on the Executive Committee of the personalized medicine initiative Precision Promise. Dr. Matrisian is formerly Professor and the founding Chair of the Department of Cancer Biology at Vanderbilt University. She received her PhD in molecular biology from the University of Arizona and MBA from Vanderbilt University. She is past President of the American Association of Cancer Research, a Fellow of the AACR Academy, and the recipient of the Paget-Ewing award from the Metastasis Research Society. She served as co-chair of the National Cancer Institute's Translational Research Working Group and Special Assistant to the Director of the NCI. Research in her laboratory revolved around the molecular mechanisms underlying tumor progression and metastasis, with emphasis on the biology of matrix-degrading proteinases. Pancreatic Cancer: Challenges and Solutions Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%. Although ranking 12th in terms of incidence, it is on track to become the second leading cause of cancer deaths by 2020. The Pancreatic Cancer Action Network (PanCAN) set a goal of doubling survival by 2020, identified 5 specific challenges that need to be addressed, and initiated approaches to contribute to their solution. There are not enough researchers or research, the clinical trial enrollment rate is too low, clinical trials need to be streamlined and focused, there is insufficient public awareness, and most patients are seen in the community setting where there is little experience with the disease. Through advocating for government resources, the NCI allocation to pancreatic cancer has increased 5-fold since 1999, with several new research initiatives that resulted from the passage of the Recalcitrant Cancer Research Act in 2013. Patient Central associates served more than 33,000 patients and families last year, providing disease and treatment information, support resources, and clinical trial searches. The Patient Registry collects information from individual patients, learns best practices, and disseminates information on topics such as the use of pancreatic enzyme replace therapy to the scientific community. The Know Your Tumor ® initiative has enrolled more than 1300 patients from across the US, and delivered almost 700 reports thus far detailing the results from genomic and proteomic analysis of tumor tissue with treatment options based on the molecular profiling and consideration of treatment history. These results indicate that 25% of pancreatic cancer patients have “actionable alterations” that indicate a targeted therapy, and that the median progression-free survival of patients that utilize a report-directed targeted therapy increased by 46% over those with no highly actionable alteration. The clinical trial landscape in pancreatic cancer has changed over the past 5 years, with a doubling of those trials that test a targeted therapy and an increase in trials for recurrent disease. The accrual of pancreatic adenocarcinoma patients to clinical trials increased from 3.8% in 2011 to 4.2% in 2014; this is at least in part attributed to increased awareness of clinical trials through PanCAN’s Clinical Trial Finder (12% of those who access this service enroll in a clinical trial) and Know Your Tumor ® initiatives (21% of participants enroll in a clinical trial). PanCAN is initiating Precision PromiseSM , a clinical trial and research platform with the mission of continuously and rapidly evaluating novel treatment options for pancreatic cancer. Public awareness of the disease is raised... Earn PACE/CME Credits: 1. Make sure you’re a registered member of LabRoots : https://www.labroots.com/virtual-event/cancer-research-oncology-2017 2. Watch the webinar on YouTube above or on the LabRoots Website : https://www.labroots.com/virtual-event/cancer-research-oncology-2017 3. Click Here to get your PACE October 12, 2019 – http://www.labroots.com/credit/pace-credits/2532/third-party LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Просмотров: 81 LabRoots
On January 26, 2013 we held the 9th Annual Hirshberg Symposium for Pancreatic Cancer Research at the UCLA Faculty Center. The five hour event was designed for pancreatic cancer specialists to discuss, share and answer questions on Advances in Pancreatic Cancer Management. The program was exclusively for patients, families, caretakers and those that have been touched by pancreatic cancer to receive informed updates in lay-terms from leading doctors and researchers. Because of the quality of our program, about forty physicians and scientists from the medical community also attended. The symposium began with opening remarks from Agi Hirshberg, Dr. Vay Liang W. Go, Chief of the Hirshberg Scientific Advisory Board, and A. Eugene Washington, Dean of the UCLA School of Medicine, who spoke briefly about the importance of the partnership between the Hirshberg Foundation and UCLA. The first speaker was Dr. O Joe Hines from UCLA who talked about the Surgical Management of Pancreatic Cancer, followed by Dr. Teri Brentnall from University of Washington who discussed Early Detection and Genomic Medicine. Dr. Lee Rosen then informed our audience about Chemotherapeutic Management of Pancreatic Cancer while the Psychosocial Management of the disease was presented by Dr. Kauser Ahmed. The final speaker was Dr. Diane Harris from the Center for Disease Control and Prevention, who discussed cancer prevention and a healthy diet. After the five speakers there was a question and answer session where patients were able to ask our panel questions in a comfortable environment. We ended our Symposium with a healthy lunch in the UCLA Faculty Center. There was no cost to attend this event, which was sponsored in part by Genentech and Celgene. To view the video presentations, please click on one of the buttons below. For more information on our Symposium, please contact Allison Miller (email@example.com)
Просмотров: 200 HirshbergFoundation
#PCVTour 2015. Meet Eric & Liz McIntyre from Metairie, LA and learn about their remarkable journey that begins on April 19th. One man on a mission: Cycle 75 miles a day through 18 states for 3 ½ months to raise funds and awareness in support of pancreatic cancer patients, like Liz, and to deliver a message of hope and progress... With little experience as an endurance athlete, 57-year old Eric McIntyre will cycle throughout the United States with his wife Liz in the support car as much as her treatments will allow. Taking a stand against cancer, their mission is to inspire others battling pancreatic cancer, to raise awareness about the developments in treatment resources, and to raise funds to help those with cancer to get to FDA clinical trial treatments. The funds raised will benefit Lazarex Cancer Foundation (LCF); a publicly funded 501(c)3 nonprofit based in Danville, CA. Through LCF 100% of the monies raised will go directly to cancer patients to defray the necessary but prohibitive costs of traveling for FDA treatment trials. https://www.lazarex.org Support the PCVTour: https://www.crowdrise.com/pcvtour Find out more about the PCVTour: http://www.lazarex.org/events/pancreatic-cancer-victory-tour Video filmed by Tod Hillman March 2015
Просмотров: 363 Pancreatic Cancer Victory Tour (PCVT)
Presented By: Kristin G. Anderson, PhD - Postdoctoral Research Fellow, University of Washington and Fred Hutchinson Cancer Research Center Speaker Biography: Dr. Kristin G. Anderson is a Senior Postdoctoral Research Fellow in the Clinical Research Division of the Fred Hutchinson Cancer Research Center and in the Immunology Department of the University of Washington in Seattle, WA. Her research investigates strategies for treating solid tumors with adoptive T cell therapy. Currently, she is developing molecular engineering strategies to improve tumor eradication with genetically engineered cells in ovarian cancer, with the ultimate goal of translating her findings into treatment protocols for patients. Her team uses cutting-edge technologies, including deep transcriptome profiling and single cell RNA sequencing, to elucidate the molecular mechanisms driving T cell dysfunction in ovarian cancer. Using mouse models of cancer that recapitulate the hallmark immunosuppressive mechanisms in human disease, she is exploring strategies that improve the migration, persistence and function of genetically engineered T cells within solid tumors. While her findings are intended to inform the development of new immunotherapies for treating ovarian cancer patients, the mechanisms under investigation are operative in many solid tumors and her advances will likely have applicability to many other malignancies. Webinar: Pre-clinical T cell immunotherapy strategies for overcoming immunosuppression in solid tumors Webinar Abstract: Engineered T cells expressing a tumor antigen-specific receptor have revolutionized the field of cancer therapy for blood cancers. However, similar success has not generally been obtainable in solid tumors, in which the tumor microenvironment (TME) exhibits immunosuppressive effects against injected therapeutic T cells. Our studies have utilized mouse models demonstrated to recapitulate the immunosuppressive features of human cancers to test novel immunotherapy strategies, either alone or in combination. Strategies that incapacitate specific immune-inhibitory pathways operative in the TME can enhance T cell function and improve anti-tumor efficacy. Our results suggest such efforts will soon lead to translation of effective immunotherapies for human solid tumors. In this webinar, the speaker will: -Explain how analysis, including by transcriptome profiling, of appropriate immunocompetent models and human tissues can be used to predict obstacles to therapeutic human T cell function -Describe strategies for overcoming immunosuppressive TME features -Provide examples in ovarian and pancreatic cancer models of novel T cell engineering that improves the efficacy of adoptive T cell therapy *For Research Use Only. Not for use in diagnostic procedures.* Earn PACE Credits: 1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/ms/webinar/pre-clinical-cell-immunotherapy-strategies-overcoming-immunosuppression-solid-tumors) 2. Watch the webinar on YouTube or on the LabRoots Website (https://www.labroots.com/ms/webinar/pre-clinical-cell-immunotherapy-strategies-overcoming-immunosuppression-solid-tumors) 3. Click Here to get your PACE credits (Expiration date – April 26, 2020 08:00 AM): https://www.labroots.com/credit/pace-credits/2796/third-party LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Просмотров: 36 LabRoots
Joo Ha Hwang, M.D., Ph.D., University of Washington, a leading focused ultrasound researcher and gastroenterologist talks about searching for a new treatment option for Pancreatic Cancer.
Просмотров: 1305 Focused Ultrasound Foundation
The Rolfe Pancreatic Cancer Foundation was founded in 1999 by the family and friends of Michael Rolfe who died of pancreatic cancer two weeks after diagnosis. The Rolfe Foundation (headquartered in Chicago) raises charitable dollars to provide grants to top-tier medical institutions for innovative research in early detection pancreatic cancer. The Foundation also partners with organizations that offer specialized support services for patients and families. Currently, the Foundation supports pancreatic cancer labs at Johns Hopkins Medical Institutions, The University of Chicago and Ohio State University. Since inception the Rolfe Foundation has raised close to $5 million toward its mission.
Просмотров: 737 RolfeFoundation
The Biliscreen App can detect early signs of pancreatic cancer. Diagnose with your smartphone using the Biliscreen app. It can diagnose the creatinine or bilirubin level and detect when the level is too high. Selfies could help detect pancreatic cancer! The app's name Biliscreen comes from the word bilirubin, a brownish yellow substance found in bile also called jaundiced, a yellowish or greenish pigmentation of the skin and whites of the eyes due to high bilirubin levels. For more information about this amazing creation visit the publication by the University of Washington : https://goo.gl/YDkjPu Symptoms of pancreatic cancer: * Yellowing of the skin or the white of the eyes * Pain in the upper or middle abdomen and back * Mysteriously weight loss * Loss of appetite * Fatigue * Depression For more info visit the website of the American Cancer Society https://goo.gl/NdZN2D ❗ Join the live stream vocally. Download the free app here : https://discord.gg/S5Bp5bP and join 💪 JOIN THE CLUB 💪 I work hard to remain independent from Youtube. My future is a television studio live streaming to Youtube with an unique business model. Your support is greatly appreciated, you can support and protect my dream, my passion, my future by joining my official Patreon page. For a lousy $1 you get the following great advantages: ✅ 8 amazing rewards to choose from ✅ Monthly live sessions ✅ Free downloads (E-learning and Autobiography) ✅ Direct in contact with me ✅ Dosis bloopers ✅ Behind the scenes ✅ Underground publications ✅ You're official sponsor of Lions Ground ✅ You become part of the board and make decisions with Lions Ground ✅ Become moderator at Discord Join here : https://www.patreon.com/lionsground Thank you for supporting me on Patreon: Dennis Buck CaptLateNight CJ Heather D Stupelli Israel Hand (Azmeric Studios) Jack Dale Jocelyn Elliott Ken Berlick Keith Schortzmann Leonard mott Paul Mabbott Peter Huygen Ricky Singh Tyler Thomas Maryann Palmer 🔹FACEBOOK GROUP https://www.facebook.com/groups/lionsground/ 🔹FACEBOOK PAGE https://www.facebook.com/lionsground/ 🔹TWITTER https://twitter.com/lionsground 🚫 If I miss any advertising / disrespectful comments to anyone make sure to flag them, we're here to enjoy the videos! 🔕 CREDITS ☷☷☷☷☷☷ Hidden Agenda by Kevin MacLeod is licensed under a Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) Source: http://incompetech.com/music/royalty-free/index.html?isrc=USUAN1200102 Artist: http://incompetech.com/
Просмотров: 692 Lions Ground
MedStar Georgetown University Hospital is proud to introduce proton therapy with HYPERSCAN™ technology to its suite of comprehensive treatments. The new addition makes the Hospital the first and only proton therapy site in the Washington, D.C., metropolitan area, greatly enhancing the care and convenience of patients throughout the region. Proton therapy is a highly advanced form of radiation treatment that targets tumors anywhere in the body in both adults and children. For more information, call 202-444-4639 or visit: MedStarGeorgetown.org/ProtonCenter
Просмотров: 6504 MedStar Georgetown University Hospital
A Selfie Can Help You Detect Pancreatic Cancer With a survival rate of just 9 percent, pancreatic cancer has one of the worst prognosis. But now your smartphone will help you detect this disease in early stages, that too by just taking a selfie with Biliscreen. SEATTLE — Researchers at the University of Washington have developed a smartphone app that could detect the early signs of pancreatic cancer by analyzing users' selfies. Bilirubin is a bile pigment produced when the liver breaks down old red blood cells. One of the symptoms of pancreatic cancer is jaundice, caused by an accumulation of bilirubin in the body. --- Please Subscribe My Channel: https://goo.gl/ji1WE3 --- Music: In The Field of Audionautix Creative Commons Attribution (https://creativecommons.org/licenses/by/4.0/) Singer: http://audionautix.com/
Просмотров: 22 The H
Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses the trial design and results of the phase III NAPOLI-1 trial that examined MM-398 with 5-fluorouracil (5-FU) and leucovorin in patients with metastatic pancreatic cancer following gemcitabine-based therapy. To view more from the World GI Congress, visit http://www.onclive.com/conference-coverage/world-gi-2014
Просмотров: 557 OncLiveTV
YouTube Live Thursday, January 12, 2017 2:30 - 3:30pm ET Prostate cancer experts William Dahut, M.D. of the National Cancer Institute and Dr. Heather Cheng, M.D. of the University of Washington discuss current and future research areas and treatment options for prostate cancer. The panel was moderated by Ana Fadich, MPH, CHES Vice President at Men’s Health of the Men's Health Network. http://www.cancer.gov/prostate http://www.cancer.gov/social-media/events
Просмотров: 5066 National Cancer Institute
Dr. David Maloney, an associate professor of medicine at the University of Washington and medical oncologist at Seattle Cancer Care Alliance, discusses his excitement over CAR (chimeric antigen receptor) T-cell therapy. As a leader in this research, Dr. Maloney describes the wave of research efforts behind this adoptive T-cell therapy using the patients own immune cells to fight back against the cancer, including blood cancers like lymphoma and chronic lymphocytic leukemia (CLL). Dr. Maloney provides insight on the process of collecting T-cells and what the future holds for CAR T-cell therapy and its potential extension to not only blood cancers, but perhaps broadening its application in lymphoma, lung, ovarian and other solid tumors. View Dr. Maloney's profile: http://www.seattlecca.org/doctor/david-g-maloney.cfm View information about Dr. Maloney's T-cell trial: http://www.seattlecca.org/clinical-trials/lymphoma-NCT01865617.cfm Learn more about CAR T-cell therapy: http://www.seattlecca.org/diseases/immunotherapy-t-cell-therapies.cfm View a photo of a scan that shows the results of this promising therapy: https://twitter.com/HutchinsonCtr/status/453205116829454336/photo/1
Просмотров: 7616 Seattle Cancer Care Alliance
When Bev Sodemann was diagnosed with pancreatic cancer in 2008, her disease was advanced. With T3 node-positive tumors, her survival rate would have been five percent or less just several years ago. As of today, and due to significant findings in cancer research, this number has grown to ten percent or higher. "Like so many patients who go through really challenging things, time takes on a new meaning," says her doctor, Willian Hawkins, MD, a Siteman Cancer Center surgeon and researcher and Chief of the section of hepatobiliary-pancreatic and gastrointestinal surgery at Washington University School of Medicine. With funding from the Cancer Frontier Fund in 2010, Hawkins developed a new treatment strategy for pancreatic cancer, utilizing the body's own immune system. Thus far, this strategy has shown the best results they've seen. Today, Bev is grateful for the precious gift that cancer research has given her; the gift of time.
Просмотров: 244 Siteman Cancer Center
Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a trial looking at PF-04136309, an investigational chemokine receptor antagonist, in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer. More from this conference: http://www.targetedonc.com/conference/gi-2015
Просмотров: 154 Targeted Oncology
In 2010 I accidentally stumbled upon the movie "Run from the Cure" on YouTube. I was very skeptical when I initially heard that cannabis could cure cancer. Like everyone, I assumed that if there was a cure for cancer it wouldn't be kept quiet. After countless hours of watching videos and reading through articles and studies I began to change my opinion. There was so much science behind cannabis and its effects on cancer I couldn't believe it. Since 1974 studies have shown that cannabis has anti-tumor effects. The results of the 1974 study, reported in an Aug. 18, 1974, Washington Post newspaper feature, were that cannabis's component, THC, "slowed the growth of lung cancers, breast cancers and a virus-induced leukemia in laboratory mice, and prolonged their lives by as much as 36 percent." In 1975 an article in the Journal of the National cancer institute titled "Antineoplastic Activity of Cannabinoids," they reported that "Lewis lung adenocarcinoma growth was retarded by the oral administration of tetrahydrocannabinol (THC) and cannabinol (CBD). Mice treated for 20 consecutive days with THC and CBD had reduced primary tumor size." In 1998, a research team at Madrid's Complutense University Led by Dr. Manuel Guzman discovered that THC can selectively induce programmed cell death in brain tumor cells without negatively impacting surrounding healthy cells. They reported in the March 2002 issue of "Nature Medicine" they had destroyed incurable brain cancer tumors in rats by injecting them with THC. And in 2007 even Harvard Researchers found that compounds in cannabis cut the growth of lung cancer. There is also an organization called The SETH Group that showed compounds in cannabis can stop the growth of human glioblastoma multiforma (GBM) brain cancer cells. The SETH Group says "No chemotherapy can match this nontoxic anti-cancer action." Even last year in 2012 a pair of scientists at California Pacific Medical Center in San Francisco found THC stops metastasis in many kinds of aggressive cancer. Those are just a few of the studies done that show the effects of cannabis on cancer. Even after all of the research behind this it seemed that this treatment was being ignored. So over the next year and a half I began talking about this to pretty much anyone that would listen and found that like myself, most people had not heard anything about cannabis oil as a treatment for cancer. In November 2011 all of that talking finally reached the right person. I was contacted by a man who was looking for help. This man wishes to remain anonymous so I'll refer to him as Bob. Bob had stage 4 cancer in his stomach, throat and pancreas. Over the course of about 6-8 weeks from when Bob was diagnosed, he became so sick he could no longer eat and he lost over 50lbs. He was actually supposed to be dead before thanksgiving and when i first talked to him he was given about 2 weeks to live. Bob had been given radiation the month before he contacted me and he and his doctor were hopeful that would help. But instead of helping it seemed to make his cancer worse. So instead of trying to continue to help Bob, his doctor told him he was sorry but the cancer had spread too much and there was nothing left to do for him. Bob's doctor simply told him to go home and die. Click below to read the rest... - See more at: http://www.cureyourowncancer.org/lincolns-story-why-cyoc-started.html#sthash.cxJppMQy.dpuf
Просмотров: 97338 Lincoln Horsley
"Targeted Capture and Massively Parallel Sequencing for Genetic Testing of Breast and Ovarian Cancer" Tomas Walsh, Research Asst. Professor with UW Medicine, describes the development of a comprehensive genetic test for inherited breast and ovarian cancer. The assay, called BROCA, uses DNA capture and next generation sequencing technology and is highly sensitive for identifying mutations in a panel of 21 tumor suppressor genes, including BRCA1, BRCA2, and other genes known to cause inherited breast or ovarian carcinoma. In the present study, BROCA is applied to analyze the germline DNA from 360 women undergoing surgery for primary ovarian, peritoneal, or fallopian tube carcinoma at the University of Washington.
Просмотров: 930 UW Video
On October 3, 2011, Cancer Research Institute (CRI) presented the William B. Coley Award for Distinguished Research in Tumor Immunology jointly to Philip D. Greenberg, M.D., and Steven A. Rosenberg, M.D., Ph.D., for their pioneering work in the development of adoptive immunotherapies for the treatment of cancer. Greenberg is a professor of medicine (oncology) and immunology at the University of Washington and head of the immunology program at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Rosenberg is head of tumor immunology and chief of surgery at the National Cancer Institute in Bethesda, Maryland.
Просмотров: 380 Cancer Research Institute
Sunil K. Aggarwal, MD, PhD, FAAPMR Palliative Medicine Physician and Associate Hospice Medical Director MultiCare Auburn Medical Center Sunil K. Aggarwal, MD, PhD, FAAPMR is a Palliative Medicine Physician and Associate Hospice Medical Director at MultiCare Auburn Medical Center in Washington state. A NIH Medical Scientist Training Program Fellowship graduate, Dr. Aggarwal received his PhD in 2008 and MD in 2010 from the University of Washington (UW). He completed his Residency in Physical Medicine and Rehabilitation at NYU Langone Medical Center, where he was a finalist for Resident of the Year. He completed a Clinical Fellowship in Hospice and Palliative Medicine at the NIH Clinical Center. He has published over two dozen peer-reviewed articles and chapters. A graduate of the Oklahoma School of Science and Mathematics, Dr. Aggarwal received a BS (Chemistry, High Honors), a BA (Philosophy, With Distinction in General Scholarship) and a minor in Religious Studies from UC Berkeley. As an NSF Graduate Research Fellow, he wrote a PhD dissertation entitled ‘The medical geography of cannabinoid botanicals in Washington state: Access, delivery, and distress”, conducted under NIH first-issued federal Certificates of Confidentiality. Dr. Aggarwal successfully led the effort to get the AMA to call in 2009 for a review of the Scheduling classification of cannabis, their first such statement in 72 years. He serves on the Editorial Advisory Board of the National Cancer Institute’s PDQ Cancer CAM information summary on cannabis and cannabinoids. He has been invited to speak on ‘Cannabis and Pain’ by Congressional Black Caucus Health Conference. He is an Affiliated Faculty of the MultiCare Institute for Research and Innovation, and an Invited Affiliate Assistant Professor in the UW Department of Geography, an Associate Member of the Humboldt Institute for Interdisciplinary Marijuana Research & the NY Academy of Medicine, an Honorary Trustee of the Medicinal Cannabis Foundation of India, and Vice-President of the Washington Physicians for Social Responsibility. (www.cannabinologist.org) Visit us at Canlio.com
Просмотров: 1405 Canlio
Dr Tony Talebi discusses the treatment of Non Seminoma Testicular Cancer with Dr Benedetto. For further discussion visit http://www.HemOnc101.com Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084 Treatment of non seminoma testicular cancer Testicular cancer is the most common solid malignancy affecting males between the ages of 15 and 35, although it accounts for about 1 percent of all cancers in men. Germ cell tumors (GCTs) account for 95 percent of testicular cancers. They may consist of one predominant histologic pattern, or represent a mix of multiple histologic types. For treatment purposes, two broad categories of testis tumors are recognized: pure seminoma (no nonseminomatous elements present), and all others, which together are termed nonseminomatous germ cell tumors (NSGCTs). In most series, the ratio of seminoma to NSGCT is about one. Testicular cancer has become one of the most curable of solid neoplasms because of remarkable treatment advances beginning in the late 1970s. Here, Dr. Tony Talebi discusses the treatment of non seminoma testicular cancer with Dr. Pasquele Benedetto, professor of medicine at the University of Miami Sylvester Comprehensive Cancer Center, including symptoms, diagnosis, staging, prognosis, surgery, radiation therapy and chemotherapy for non seminoma testicular cancer. Dr. Pasquele Benedetto credentials: Board Certifications: American Board of Internal Medicine American Board of Internal Med-Hematology American Board of Internal Med-Medical Oncology Education: Georgetown University Washington, DC Undergraduate Weill Medical College of Cornell University New York, NY Graduate Johns Hopkins Hospital Baltimore, MD Residency Memorial Sloan-Kettering Cancer Center New York, NY Fellowship
Просмотров: 3263 Tony Talebi, MD
BRCA genes / Â lifestyle factors and PARP inhibitors Response by: Mary-Claire King, PhD (from the audience) American Cancer Society Professor, Departments of Medicine and Genome Sciences, University of Washington, Seattle, WA Alan Ashworth, BSc, PhD, FRS (from the audience) Professor, Molecular Biology and Director, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
Просмотров: 632 Breast Cancer Research Foundation
Professor Hong Chen at Washington University in St. Louis reached across disciplines, and within her own department, to work toward a more focused drug delivery system that could target tumors lodged in the brainstem, the body's most precious system. The new system may lead to novel treatments for diffuse intrinsic pontine gliomas (DIPG), a devastating, childhood brain cancer. https://source.wustl.edu/2018/09/focused-delivery-for-brain-cancers/
Просмотров: 1394 Washington University in St. Louis
Patricia Purcell, pancreatic cancer survivor addresses the 2011 Seen Magowitz Foundation Golf Classic Luncheon. Diagnosed with pancreatic cancer, she was given months to live. She contacted Dr. Daniel Von Hoff for treatment and not only has she survived well over a year but now is in remission.
Просмотров: 1233 Donovan's Steakhouse
Cancer experts will sometimes tell you that every patient's cancer is a snowflake, each case unique in its own way. With oncologists needing to consider all the individual elements to a patient's cancer, Microsoft researcher Hoifung Poon, along with his colleagues, has developed a system that uses machine learning to sort through the massive volumes of cancer research that might apply to a particular case. This system could help an oncologist more quickly cut through data, creating personalized cancer treatment plans that more effectively treat each unique cancer. Learn more how technology is helping personalize cancer treatment: http://news.microsoft.com/stories/computingcancer Project Hanover: http://hanover.azurewebsites.net/
Просмотров: 5639 Microsoft Research
University of Washington researchers have developed a smartphone app that accurately measures jaundice in adults using a selfie and an accessory. BiliScreen is a non-invasive alternative to to blood draws for measuring bilirubin levels in the blood stream. Excess bilirubin can be an indicator of a variety of health conditions - including pancreatic cancer, a disease that often goes undetected until it is in an advanced stage, when jaundice is visible to the naked eye. BiliScreen can be used anytime, anywhere in conjunction with either a 3D-printed box or color-calibrated glasses to account for different lighting conditions.
Просмотров: 45588 Paul G. Allen School
Each year, the Illumination Gala to raise money for cancer research at the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine through The Foundation for Barnes-Jewish Hospital. Since 2007, the event has raised more than $22 million through donor generosity. Cancer is personal. Many of us have either been touched directly by cancer or have family or friends who have been impacted by this devastating disease. Through the Illumination Gala, the community joins together to make a difference by supporting groundbreaking cancer research to develop better ways to prevent and treat cancer.
Просмотров: 86 Siteman Cancer Center
Genomic sequencing technologies have enabled increasing use of cancer genetic testing for both inherited cancer predisposition and somatic mutation profiling in tumors. This presentation reviews interplay between germline and somatic findings in cancer genetic testing, with particular emphasis on new areas of clinical utility. These new areas include germline testing of cancer predisposition genes to guide cancer treatment decisions, tumor DNA sequencing to rule out Lynch syndrome, and tumor DNA sequencing used to inform germline variant classification. Colin C. Pritchard, MD, PhD Associate Professor Director of Clinical Diagnostics, Brotman Baty Institute for Precision Medicine Co-Director, Genetics and Solid Tumors Laboratory Head, Genetics Division Dept. of Laboratory Medicine University of Washington 10/17/18 http://depts.washington.edu/labweb/Education/ContEdu/ http://uwtv.org
Просмотров: 53 UW Video
Assistant Professor, Radiation Oncology Specialties: Radiation Oncology Clinical Interests: Gastrointestinal cancer (including liver, pancreas, rectal, anal, and bile duct) and sarcoma Dr. Mary Feng, Associate Director of Clinical Research, received her undergraduate degree from Stanford University and her medical degree from Washington University in St. Louis. She arrived at the University of Michigan in 2001, first for an Internal Medicine internship, then for her Radiation Oncology residency. She is board certified in Radiation Oncology and an Assistant Professor at the University of Michigan. Her clinical specialties are the treatment of gastrointestinal cancers (including liver, pancreas, rectal, anal, and bile duct) and sarcomas, either with radiation alone or in combination with chemotherapy. Her research interests include technical and biological methods to individualize and adapt radiotherapy for each patient with liver cancer to maximize both the effectiveness and safety of treatment. She also is heavily involved in the integration of the latest cutting-edge technologies into the treatment of all cancer patients.
Просмотров: 586 Michigan Medicine
https://www.ibiology.org/genetics-and-gene-regulation/canine-genetics Elaine Ostrander provides an overview of canine genetics, and explains how scientists are using genetics to decipher the molecular basis of different traits such as height and cancer risk. Talk Overview: Although all domestic dogs belong to the same species, different breeds display unique morphological traits and different disease susceptibility. Dr. Elaine Ostrander provides an overview of canine genetics, and explains how scientists are using genetics to decipher the molecular basis of different traits such as height and cancer risk. In her second lecture, Ostrander explains that canine genetics can be used to understand disease susceptibility and cancer risk. By analyzing the pedigree of dogs, her laboratory identified a series of genes involved in the elevated cancer risk of particular dog breeds. Specifically, her laboratory studied invasive transitional cell carcinoma of the bladder, a disease for which breeds like Scottish Terriers have a high susceptibility. In human cases of this disease, the cause is unknown in 50% of patients. Ostrander’s laboratory identified genetic mutations that explain the elevated cancer risk in these dogs. This information may improve diagnosis and targeted therapy in dogs and humans. Speaker Biography: Dr. Elaine Ostrander is the Chief and Distinguished Investigator at the National Human Genome Research Institute at the National Institutes of Health (NIH). She received her B.S. degree from the University of Washington (1981), and her Ph.D. from the Oregon Health & Science University (1987). Ostrander continued her postdoctoral training at Harvard University. A few years later, she joined the Lawrence Berkeley National Labs at University of California, Berkeley, where she began the canine genome project. In 2004, she joined the NIH and her laboratory studies the domestic dog as a model organism to understand the heritability of traits and disease susceptibility. For her scientific contributions, she was named NIH Distinguished Investigator (2011). Visit her lab website and learn more about Ostrander’s research: https://www.genome.gov/12513335
Просмотров: 2074 iBiology
David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the success and challenges of CAR T-cell therapy in hematologic malignancies.
Просмотров: 98 OncLiveTV
Google Tech Talk July 29, 2008 ABSTRACT Dr. Elmer E. Huerta is the Principal Investigator (PI) of the Latin American Cancer Research Coalition (LACRC) and a member of the LACRC Steering Committee. He is currently the President of the American Cancer Society and the Founder and Director of the Cancer Preventorium at the Washington Cancer Institute in the Washington Hospital Center, the only cancer prevention/screening service for Latinos in the Washington, DC, metropolitan area. The goal of the clinic is to encourage preventive screenings; therefore, the clinic is open to patients who do not have any disease symptoms. Born in Peru, Dr. Huerta obtained his medical degree at the University of San Marcos in 1981. Trained in Internal Medicine and Medical Oncology in Peru, he completed a fellowship in oncology research at the Johns Hopkins Oncology Center in 1988, a residence in internal medicine at St. Agnes Hospital in 1991, an M.P.H. at the Johns Hopkins School of Hygiene and Public Health in 1992, and a fellowship in Cancer Prevention and Control at the National Cancer Institute in 1994. Through his educational work, Dr. Huerta has gained a high degree of respect and trust in the Hispanic community at the local, national, and international levels. Since 1989, Dr. Huerta's daily radio show Cuidando su Salud (Taking Care of Your Health) has provided daily disease prevention and health promotion messages to Hispanics on a Washington, DC-area Spanish-language station. Dr. Huerta also hosts El Consultorio Comunitario (The Community Clinic of the Air), a daily talk radio program, and cohosts Hablemos de Salud (Let's Talk About Health), a weekly television program. In the Washington area, the programs can be found on Radio America 1540 AM and Telemundo, respectively. His shows, which are syndicated nationally, reach 90 percent of the Spanish-speaking population in the United States and are distributed throughout Latin America. About Perspectivas Speaker Series: Perspectivas is a speaker series aimed to empower and inspire individuals by providing 'mentoring at scale'. Latino scientists and professionals share their perspectives on careers, work-life balance, and how they've achieved personal success. More videos on this series: http://www.youtube.com/view_play_list?p=278FED82770E323B
Просмотров: 34484 GoogleTechTalks
C. Jimmy Lin, MD, PhD, MHS is the Chief Scientific Officer (CSO), Oncology at Natera and a TED Fellow. He comes from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Previously, at Johns Hopkins and Washington University in St. Louis, Lin was part of one of the first clinical genomics labs in academia and led the computational analyses of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma and melanoma. Jimmy Lin, MD, PhD, MHS, ha dedicado su vida a la lucha contra el cáncer. Como jefe de ciencias y oncología en Natera (NASDAQ: NTRA), ha liderado el desarrollo en tecnologías para la detención de células cancerígenas en la sangre. Es fundador/presidente del Instituto de Genomas Inusuales, la primera plataforma en el mundo que permite a cualquier comunidad, el acceso a biotecnología para el entendimiento de diferentes enfermedades. Geneticist and founder of the Rare Genomics Institute, an organization that allows patients to crowdsource funds and genomes to accelerate research of their rare genetic diseases. Jimmy is the lead computational biologist for the ground-breaking cancer genome sequencing efforts from the Vogelstein Lab at Johns Hopkins. Their sequencing of the first 100+ cancer exomes in 5 different tissue types has helped lay the foundation for a revolution in cancer genomics. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx
Просмотров: 278 TEDx Talks
How has gene expression profiling impacted the way we diagnose and treat breast cancers? Kimberly Allison, MD, Assistant Professor, Department of Pathology at the University of Washington discusses how research using gene expression signatures have been used to identify specific subtypes of breast cancer and how these are integrated into traditional classification schemes. In addition, we will explore the development of clinically available gene expression array-based tests that are designed to give prognostic and predictive information tailored to individual breast cancer patients and discuss current limitations of these tests." To see more videos from the University of Washington visit uwtv.org.
Просмотров: 1790 UW Video
Last year's annual Student Research and Creative Activity Expo marked the largest exhibition of original student research, scholarship, and creative work to date. Prize-winning projects ranged from a documentary film on Ohio's controversial role in the 2004 election to a new treatment for pancreatic cancer, to a study on optimizing fuel cells that uses alternative energy sources. Explore new student discoveries and work at the 2008 Research and Creative Activity Expo on Thursday, May 15 at the Convocation Center from 12:30 p.m. to 2:30 p.m.
Просмотров: 327 ohioweb
Part of our mission is to transform cancer patient care through scientific discovery. Over the years, researchers at Siteman and Washington University have pioneered research that led to advances in patient care. And today, we carry that same pioneering spirit in how we approach new therapies.
Просмотров: 202 Siteman Cancer Center
Dr. Philip J. Gold is a medical oncologist at Swedish Cancer Institute, program leader for the GI oncology program, and medical director for the clinical research program. His practice focuses on gastrointestinal oncology. Dr. Gold helps patients understand why they are being treated and the goals of therapy. Swedish Cancer Institute's multidisciplinary expertise allows Dr. Gold to consult with colleagues to deliver the most appropriate treatment. His goal is compassionate, personalized medicine and state-of-the-art care. Dr. Gold also provides treatment for Colorectal Cancer, Esophageal Cancer, Gastrointestinal Cancer, Hepatocellular Carcinoma and Pancreatic Cancer treatment. For more information about Dr. Gold visit http://www.swedish.org/Physicians/Philip-Gold.
Просмотров: 1471 swedishseattle